Literature DB >> 2655690

Cyclosporin-erythromycin interaction in renal transplant patients.

S K Gupta1, A Bakran, R W Johnson, M Rowland.   

Abstract

1. The interaction between cyclosporin (CyA) and erythromycin was studied in renal transplant patients following oral and intravenous administration of CyA. 2. Blood and plasma CyA concentrations and blood concentrations of metabolite 17 were measured by h.p.l.c. 3. Erythromycin produced almost a two-fold increase in bioavailability, from 36% to 60%; with a small (13%) decrease in clearance of CyA. 4. The metabolite 17 data further support the postulate that erythromycin increases the absorption of CyA rather than inhibits its metabolism, as generally believed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2655690      PMCID: PMC1379727          DOI: 10.1111/j.1365-2125.1989.tb05396.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment.

Authors:  B Legg; M Rowland
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

2.  New method for calculating the intrinsic absorption rate of drugs.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1968-06       Impact factor: 3.534

3.  Erythromycin and cyclosporine.

Authors:  T A Gonwa; D D Nghiem; J A Schulak; R J Corry
Journal:  Transplantation       Date:  1986-06       Impact factor: 4.939

4.  Extraction ratio of cyclosporine in a liver transplant patient with organ rejection.

Authors:  R Venkataramanan; R J Ptachcinski; G J Burckart; S Yang; T E Starzl
Journal:  J Pharm Sci       Date:  1985-08       Impact factor: 3.534

5.  The effects of erythromycin in patients treated with cyclosporine.

Authors:  R Martell; D Heinrichs; C R Stiller; M Jenner; P A Keown; J Dupre
Journal:  Ann Intern Med       Date:  1986-05       Impact factor: 25.391

6.  Cyclosporine monitoring in liver transplant patients.

Authors:  W Andrews; S Iwatsuki; B W Shaw; T E Starzl
Journal:  Transplantation       Date:  1985-03       Impact factor: 4.939

7.  Effect of erythromycin on cyclosporine levels.

Authors:  R J Ptachcinski; B J Carpenter; G J Burckart; R Venkataramanan; J T Rosenthal
Journal:  N Engl J Med       Date:  1985-11-28       Impact factor: 91.245

8.  Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites.

Authors:  G Maurer; H R Loosli; E Schreier; B Keller
Journal:  Drug Metab Dispos       Date:  1984 Jan-Feb       Impact factor: 3.922

Review 9.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

Review 10.  Pharmacokinetic interactions of the macrolide antibiotics.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

View more
  22 in total

Review 1.  The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

Authors:  Margaret M Doherty; William N Charman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.

Authors:  K Ito; H Kusuhara; Y Sugiyama
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

Review 3.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

4.  Interaction between FK506 and clotrimazole in a liver transplant recipient.

Authors:  L Mieles; R Venkataramanan; I Yokoyama; V J Warty; T E Starzl
Journal:  Transplantation       Date:  1991-12       Impact factor: 4.939

5.  Pharmacokinetics of FK 506 in transplant patients.

Authors:  R Venkataramanan; A Jain; V S Warty; K Abu-Elmagd; M Alessiani; J Lever; A Krajak; J Flowers; S Mehta; S Zuckerman
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

6.  Interaction between FK 506 and cyclosporine in dogs.

Authors:  Y M Wu; R Venkataramanan; M Suzuki; Y Zhu; H Abdallah; J Emeigh; G J Burckart; V S Warty; J J Fung; S Todo
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

7.  Loss of orally administered drugs in GI tract.

Authors:  Yogeshkumar Nanasaheb Gavhane; Adhikrao Vyankatrao Yadav
Journal:  Saudi Pharm J       Date:  2012-04-20       Impact factor: 4.330

Review 8.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

9.  A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.

Authors:  Michel Tod; S Goutelle; N Bleyzac; L Bourguignon
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

10.  Interaction between roxithromycin and cyclosporin in heart transplant patients.

Authors:  E M Billaud; R Guillemain; N Fortineau; M D Kitzis; G Dreyfus; C Amrein; C Kreft-Jaïs; J M Husson; P Chrétien
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.